Due to the use of more adjuvant therapies and the increasing prevalence of associated diseases, nontraumatic osteonecrosis of the femoral head (ONFH) has become a substantial worldwide health issue; while glucocorticoid administration was the highest-ranked risk factor, with a proportion ranging from 26.35 to 55.75%. Albeit with similar radiological features, glucocorticoid-induced ONFH (GONFH) manifested a greater probability for advance-to-late-stage (post-collapse) lesions in comparison with its non-glucocorticoid-induced counterparts. Therefore, an accurate and timely diagnosis of osteonecrosis following glucocorticoid therapy is of great significance to initiate nonoperative treatment regimens or joint-preserving procedures, slow disease progression, and defer or avert joint arthroplasty.